(Q46538027)

English

The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol

scientific article published in May 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

1 reference

based on heuristic

inferred from title

author name string

Roxana Sulica

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

Howard V Dinh

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

Kevin Dunsky

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

Valentin Fuster

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

Michael Poon

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

publication date

1 May 2005

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

Congestive Heart Failure

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

11

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

139-44; quiz 145-6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

Clinical classification of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Cellular and molecular pathobiology of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Role of pharmacologic tests in the treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Inhaled nitric oxide: basic biology and clinical applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Mechanism of action of dipyridamole

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Primary pulmonary hypertension. A national prospective study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Acute hemodynamic effects of nitroglycerin in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Hypoxic pulmonary hypertension: its modification by dipyridamole.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Diagnosis and differential assessment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2005.03885.X

21 January 2018

Identifiers

10.1111/J.1527-5299.2005.03885.X

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15947535

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46538027&oldid=2124167262"